$Vaccinex (VCNX.US)$
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer’s Disease (CTAD) Conference on October 31, 2024
Vaccinex (NASDAQ: VCNX) announced upcoming presentation of new efficacy and safety data from its SIGNAL-AD phase 1b/2 trial of pepinemab for Alzheimer's disease at the CTAD Conference in Madrid on October 31, 2024. The study focuses on pepinemab's ability to block SEMA4D, a molecule highly upregulated i...

$Vaccinex (VCNX.US)$ Why🤔

$Vaccinex (VCNX.US)$
Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership
Vaccinex (VCNX) has reported positive results from its SIGNAL-AD Phase 1b/2 trial of pepinemab in early-stage Alzheimer's disease (AD). The study showed a statistically significant difference (p=0.0297) in FDG-PET signal in the medial temporal cortex after 12 months of treatment compared to placebo. Pepinemab was well-...

$CNS Pharmaceuticals (CNSP.US)$ last discont before moon

Hello Mooers,
We’re thrilled to introduce the "Upcoming Earnings" feature – your new tool for achieving potential profits during earnings season!  
Please note that you may need to update moomoo to the latest version to use the feature below.
Why We Think You’ll Love It
🔧 Aim to Capitalize on Earnings Volatility
Earnings reports often bring big price swings. Use this feature to spot companies about to release e...